Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)

Inclusion Criteria: * Diagnosis of PXE by moleculargenetic diagnosis and/or skin biopsy * Diagnosed CNV or FVP * Age 18-65 years * Voluntary participation in this study as proven by written informed consent * Ability to follow study instructions and likely to attend and complete all required visits * Best corrected visual acuity between 20/400 and 20/20 at treated eye * Male and female patients with childbearing potential must use an approved contraceptive method (Pearl Index \< 1) before and during the trial * Pre-menopausal female patients with childbearing potential: a negative pregnancy test must be obtained Exclusion Criteria: * Subject is unable to understand the nature, scope, significance and consequences of this clinical trial * Patients with known allergy or hypersensitivity to Eylea or preparations with similar chemical structure * Treatment in another clinical trial with therapeutic intervention or use of any other investigational medicinal product (IMP) during the trial of within 30 days before enrolment * Known or persistent abuse of medication, drugs or alcohol * Women who are pregnant or breast feeding * Lack of eligibility at discretion of the investigator * Ocular operations within a month prior to enrolment * Non-controlled glaucoma * Active intraocular inflammation or inflammation of ocular adnexa * Other diseases resulting in distinct visual constraint * Distinct opacification of optical media * Distinct subretinal fibrosis and /or atrophy that prevents a relevant treatment effect by Aflibercept at discretion of investigator * Serious cardiovascular problems or stroke within 6 months before enrolment * Simultaneous use of other Vascular Endothelial Growth Factor (VEGF)-inhibiting medication (systemic or ocular) within a month prior to enrolment